Final Prospectus · 424B4
Palisade Bio, Inc.
PALINASDAQEQUITYCurrent
Final Prospectus
Company context
We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including fibrostenotic Crohn’s disease (“FSCD”) and ulcerative colitis (“UC”).
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by RA CAPITAL MANAGEMENT, L.P. regarding PALISADE BIO, INC.Nov 16, 2026
- SCHEDULE 13G/A - filed by AMERIPRISE FINANCIAL INC regarding PALISADE BIO, INC.Nov 16, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- 10-Q filingNov 10, 2026
- SCHEDULE 13G/A - filed by Commodore Capital LP regarding PALISADE BIO, INC.Aug 14, 2026
As-filed source
As filedOpen full document ↗